Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report

• Addition of plerixafor to G-CSF did not affect clinical or LT safety outcomes• No differences were noted in 5 year OS/PFS for plerixafor treated patients• No difference in composite endpoint of death, progression, or additional treatment

Source: Biology of Blood and Marrow Transplantation - February 3, 2018 Category: Hematology Authors: Ivana N. Micallef, Patrick J. Stiff, Auayporn P. Nademanee, Richard T. Maziarz, Mitchell E. Horwitz, Edward A. Stadtmauer, Jonathan L. Kaufman, John M. McCarty, Rita Vargo, Peter D. Cheverton, Martin Struijs, Brian Bolwell, John F. DiPersio Source Type: research